Cargando…
Efficacy and Safety of Switching from Tafluprost to a Tafluprost/Timolol Fixed Combination in Patients With Primary Open-Angle Glaucoma
BACKGROUND: The Tafluprost/Timolol Fixed Combination (TTFC) has demonstrated efficacy and safety in reducing Intraocular Pressure (IOP). However, direct comparisons of switching from tafluprost to TTFC are limited. OBJECTIVE: To investigate the efficacy and safety of switching from tafluprost to TTF...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Open
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047199/ https://www.ncbi.nlm.nih.gov/pubmed/30069265 http://dx.doi.org/10.2174/1874364101812010121 |
_version_ | 1783339913884729344 |
---|---|
author | Inoue, Kenji Ueda, Takeaki Ishida, Kyoko Tomita, Goji |
author_facet | Inoue, Kenji Ueda, Takeaki Ishida, Kyoko Tomita, Goji |
author_sort | Inoue, Kenji |
collection | PubMed |
description | BACKGROUND: The Tafluprost/Timolol Fixed Combination (TTFC) has demonstrated efficacy and safety in reducing Intraocular Pressure (IOP). However, direct comparisons of switching from tafluprost to TTFC are limited. OBJECTIVE: To investigate the efficacy and safety of switching from tafluprost to TTFC in patients with Primary Open-Angle Glaucoma (POAG). METHODS: Thirty-four eyes (34 patients) with POAG that did not achieve adequate IOP reduction on tafluprost were switched to TTFC with no washout period. IOP, systolic/diastolic blood pressure and pulse rate were measured 1 and 3 months later and compared with baseline values. All participants were asked about specific adverse reactions after 1 and 3 months of treatment. Patients also completed a questionnaire about preference and adherence after 1 month of treatment. RESULTS: Mean IOP after 1 and 3 months was significantly lower than at baseline (14.2 ± 2.1 mmHg and 14.1 ± 2.3 mmHg, respectively, vs 16.0 ± 2.0 mmHg, P < 0.0001). Systolic/diastolic blood pressure and pulse rate were not significantly different from baseline after 1 and 3 months. The questionnaire indicated that the frequency of missing a dose was not different before (27.3%) or after (18.2%) switching to TTFC (P = 0.2371). There were five reports of adverse reactions (14.7%), including a corneal epithelium disorder, ocular irritation, skin irritation at the wrist, and chest pain. Two patients (5.9%) withdrew because of adverse reactions. CONCLUSION: Switching from tafluprost to TTFC achieved IOP control safely and was well accepted by patients. |
format | Online Article Text |
id | pubmed-6047199 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Bentham Open |
record_format | MEDLINE/PubMed |
spelling | pubmed-60471992018-08-01 Efficacy and Safety of Switching from Tafluprost to a Tafluprost/Timolol Fixed Combination in Patients With Primary Open-Angle Glaucoma Inoue, Kenji Ueda, Takeaki Ishida, Kyoko Tomita, Goji Open Ophthalmol J Ophthalmology BACKGROUND: The Tafluprost/Timolol Fixed Combination (TTFC) has demonstrated efficacy and safety in reducing Intraocular Pressure (IOP). However, direct comparisons of switching from tafluprost to TTFC are limited. OBJECTIVE: To investigate the efficacy and safety of switching from tafluprost to TTFC in patients with Primary Open-Angle Glaucoma (POAG). METHODS: Thirty-four eyes (34 patients) with POAG that did not achieve adequate IOP reduction on tafluprost were switched to TTFC with no washout period. IOP, systolic/diastolic blood pressure and pulse rate were measured 1 and 3 months later and compared with baseline values. All participants were asked about specific adverse reactions after 1 and 3 months of treatment. Patients also completed a questionnaire about preference and adherence after 1 month of treatment. RESULTS: Mean IOP after 1 and 3 months was significantly lower than at baseline (14.2 ± 2.1 mmHg and 14.1 ± 2.3 mmHg, respectively, vs 16.0 ± 2.0 mmHg, P < 0.0001). Systolic/diastolic blood pressure and pulse rate were not significantly different from baseline after 1 and 3 months. The questionnaire indicated that the frequency of missing a dose was not different before (27.3%) or after (18.2%) switching to TTFC (P = 0.2371). There were five reports of adverse reactions (14.7%), including a corneal epithelium disorder, ocular irritation, skin irritation at the wrist, and chest pain. Two patients (5.9%) withdrew because of adverse reactions. CONCLUSION: Switching from tafluprost to TTFC achieved IOP control safely and was well accepted by patients. Bentham Open 2018-06-29 /pmc/articles/PMC6047199/ /pubmed/30069265 http://dx.doi.org/10.2174/1874364101812010121 Text en © 2018 Inoue et al. https://creativecommons.org/licenses/by/4.0/legalcode This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: (https://creativecommons.org/licenses/by/4.0/legalcode). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Ophthalmology Inoue, Kenji Ueda, Takeaki Ishida, Kyoko Tomita, Goji Efficacy and Safety of Switching from Tafluprost to a Tafluprost/Timolol Fixed Combination in Patients With Primary Open-Angle Glaucoma |
title | Efficacy and Safety of Switching from Tafluprost to a Tafluprost/Timolol Fixed Combination in Patients With Primary Open-Angle Glaucoma |
title_full | Efficacy and Safety of Switching from Tafluprost to a Tafluprost/Timolol Fixed Combination in Patients With Primary Open-Angle Glaucoma |
title_fullStr | Efficacy and Safety of Switching from Tafluprost to a Tafluprost/Timolol Fixed Combination in Patients With Primary Open-Angle Glaucoma |
title_full_unstemmed | Efficacy and Safety of Switching from Tafluprost to a Tafluprost/Timolol Fixed Combination in Patients With Primary Open-Angle Glaucoma |
title_short | Efficacy and Safety of Switching from Tafluprost to a Tafluprost/Timolol Fixed Combination in Patients With Primary Open-Angle Glaucoma |
title_sort | efficacy and safety of switching from tafluprost to a tafluprost/timolol fixed combination in patients with primary open-angle glaucoma |
topic | Ophthalmology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047199/ https://www.ncbi.nlm.nih.gov/pubmed/30069265 http://dx.doi.org/10.2174/1874364101812010121 |
work_keys_str_mv | AT inouekenji efficacyandsafetyofswitchingfromtafluprosttoatafluprosttimololfixedcombinationinpatientswithprimaryopenangleglaucoma AT uedatakeaki efficacyandsafetyofswitchingfromtafluprosttoatafluprosttimololfixedcombinationinpatientswithprimaryopenangleglaucoma AT ishidakyoko efficacyandsafetyofswitchingfromtafluprosttoatafluprosttimololfixedcombinationinpatientswithprimaryopenangleglaucoma AT tomitagoji efficacyandsafetyofswitchingfromtafluprosttoatafluprosttimololfixedcombinationinpatientswithprimaryopenangleglaucoma |